Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16562795 | 1.00 | SLC6A5 (0.41) | SLC6A5SRCTRPM8SMN1; SMN2 | |
| SCHEMBL16562877 | 1.00 | SLC6A5 (0.41) | SLC6A5SRCTRPM8SMN1; SMN2 | |
| SCHEMBL24148928 | 0.81 | TUBB4A (0.47) | — | |
| SCHEMBL17371457 | 0.81 | TUBB4A (0.47) | — | |
| SCHEMBL17135848 | 0.76 | MEN1 (0.45) | SLC6A5SMN1; SMN2 | |
| SCHEMBL19490992 | 0.76 | MEN1 (0.45) | SLC6A5SMN1; SMN2 | |
| SCHEMBL19491100 | 0.76 | MEN1 (0.45) | SLC6A5SMN1; SMN2 | |
| SCHEMBL14007278 | 0.74 | TRPA1 (0.38) | SMN1; SMN2 | |
| SCHEMBL17831977 | 0.74 | ALDH1A1 (0.51) | TRPM8SMN1; SMN2 | |
| SCHEMBL19490986 | 0.73 | PDE4D (0.40) | SLC6A5SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795583-B2 | Composition for preventing or treating heart disease | AMOREPACIFIC CORPORATION (KR) | 2017-10-24 | — | — | US | disclosed |
| US-20150283110-A1 | COMPOSITION FOR PREVENTING OR TREATING HEART DISEASE | AMOREPACIFIC CORPORATION (KR) | 2015-10-08 | — | — | US | disclosed |
| US-20150073158-A1 | METHOD FOR PREPARING FUROFURAN LIGNAN COMPOUND | AMOREPACIFIC CORPORATION (KR) | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150073158-A1 | METHOD FOR PREPARING FUROFURAN LIGNAN COMPOUND | CYP4F2, UGT1A7, UGT1A3 | SLC6A5 3796/4885SRC 4188/4885TRPM8 4134/4885 |
| US-20150283110-A1 | COMPOSITION FOR PREVENTING OR TREATING HEART DISEASE | SIRT1, SIRT3, SIRT2 | SLC6A5 4736/4885SRC 1844/4885TRPM8 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.